Second Genome Presents Preclinical Data Highlighting Potential Therapeutic Implications of Altered Gut Microbiome and Metabolites in Autism Spectrum Disorder Model and Parkinson’s Disease at The Society for Neuroscience Annual Meeting

BRISBANE, Calif.: BRISBANE, Calif., Nov. 11, 2021 /PRNewswire/ -- Second Genome, a biotechnology company that leverages its proprietary platform sg-4sight to discover and develop precision therapies and biomarkers, presented two posters at the Society for Neuroscience's (SfN) 50th Annual Meeting ("Neuroscience 2021") held virtually November 8-11. Abstract #: P045.05*Title: Predicted...

Click to view original post